Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-kappa antibody, targeting to Abeta plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Abeta as well as Abeta plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1[1][2][3][4].
Molekulargewicht:
(194.25 kDa)
Reinheit:
99.90
CAS Nummer:
[2568868-35-7]
Target-Kategorie:
Amyloid-beta
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten